This post has been archived and contains information that may be out of date.
The Drug Enforcement Administration and the Substance Abuse and Mental Health Services Administration have issued a temporary rule that extends telehealth prescribing flexibilities for buprenorphine and other controlled substances through Nov. 11, 2024.
This extension allows the telehealth prescribing flexibilities that were adopted during the COVID-19 public health emergency (PHE) to remain in effect past the end of the PHE while the agencies develop final regulations.
